Trial Profile

HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone furoate; Fluticasone propionate
Indications Asthma
Focus Pharmacogenomic; Registrational; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

24 May 2017 Results of a post-hoc analysis from NCT01165138, NCT01686633 and NCT01134042 trials presented at the 113th International Conference of the American Thoracic Society
17 Oct 2013 Results published in the European Respiratory Journal.
26 Apr 2012 Actual patient number (587) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com